| (Values in U.S. Thousands) | Mar, 2020 | Dec, 2019 | Sep, 2019 | Jun, 2019 | Mar, 2019 |
| Sales | 26,390 | 29,250 | 36,800 | 28,420 | 22,170 |
| Sales Growth | -9.78% | -20.52% | +29.49% | +28.19% | +44.90% |
| Net Income | -68,770 | -96,680 | -49,630 | -66,200 | -78,160 |
| Net Income Growth | +28.87% | -94.80% | +25.03% | +15.30% | +11.73% |
Portola Pharma (PTLA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Portola Pharmaceuticals, Inc. is a biopharmaceutical company .It focuses on the development and commercialization of therapeutics for thrombosis, other hematologic disorders and inflammation. Portola Pharmaceuticals, Inc. is headquartered in South San Francisco, California.
Fiscal Year End Date: 12/31